Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Torsten Pietsch

Showing results (181-190 of 388) with videos related to

Pageof 39
Sort By:
Clinical Neuroradiology|December 17, 2021
Magnetic Resonance Imaging Characteristics of Molecular Subgroups in Pediatric H3 K27M Mutant Diffuse Midline GliomaAnnika Hohm, Michael Karremann, Gerrit H Gielen, et al.
Acta Neuropathologica|November 20, 2010
Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomasChristian Hartmann, Bettina Hentschel, Wolfgang Wick, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2009
Activation of phosphatidylinositol-3'-kinase/AKT signaling is essential in hepatoblastoma survivalWolfgang Hartmann, Jan Küchler, Arend Koch, et al.
Translational Oncology|December 19, 2016
MTSS1 is epigenetically regulated in glioma cells and inhibits glioma cell motilityDaniel Luxen, Gerrit H Gielen, Anke Waha, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2007
Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker?Michael Weller, Hilmar Berger, Christian Hartmann, et al.
Journal of Neuro-Oncology|May 19, 2026
APTw CEST MRI in therapy-naive IDH-wildtype glioblastoma: insights into tumor heterogeneity and molecular subtypesThomas Zeyen, Andreas Decker, Inga Krause, et al.
International Journal of Cancer|March 23, 2011
Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomasJörg Felsberg, Niklas Thon, Sabina Eigenbrod, et al.
Journal of Neuropathology and Experimental Neurology|May 15, 2010
Giant cell glioblastoma is associated with altered aurora b expression and concomitant p53 mutationAchim Temme, Kathrin D Geiger, Ralf Wiedemuth, et al.
Journal of Neuro-Oncology|February 13, 2015
Disseminated oligodendroglial-like leptomeningeal tumors: preliminary diagnostic and therapeutic results for a novel tumor entity [corrected]Matthias Preuss, Holger Christiansen, Andreas Merkenschlager, et al.
Hormone Research in Paediatrics|March 4, 2010
Analyses of treatment variables for patients with childhood craniopharyngioma--results of the multicenter prospective trial KRANIOPHARYNGEOM 2000 after three years of follow-upHermann L Müller, Ursel Gebhardt, Sabine Schröder, et al.
Pageof 39

Showing results (181-190 of 388) with videos related to

Sort By:
Pageof 39
Clinical Neuroradiology|December 17, 2021
Magnetic Resonance Imaging Characteristics of Molecular Subgroups in Pediatric H3 K27M Mutant Diffuse Midline GliomaAnnika Hohm, Michael Karremann, Gerrit H Gielen, et al.
Acta Neuropathologica|November 20, 2010
Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomasChristian Hartmann, Bettina Hentschel, Wolfgang Wick, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2009
Activation of phosphatidylinositol-3'-kinase/AKT signaling is essential in hepatoblastoma survivalWolfgang Hartmann, Jan Küchler, Arend Koch, et al.
Translational Oncology|December 19, 2016
MTSS1 is epigenetically regulated in glioma cells and inhibits glioma cell motilityDaniel Luxen, Gerrit H Gielen, Anke Waha, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2007
Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker?Michael Weller, Hilmar Berger, Christian Hartmann, et al.
Journal of Neuro-Oncology|May 19, 2026
APTw CEST MRI in therapy-naive IDH-wildtype glioblastoma: insights into tumor heterogeneity and molecular subtypesThomas Zeyen, Andreas Decker, Inga Krause, et al.
International Journal of Cancer|March 23, 2011
Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomasJörg Felsberg, Niklas Thon, Sabina Eigenbrod, et al.
Journal of Neuropathology and Experimental Neurology|May 15, 2010
Giant cell glioblastoma is associated with altered aurora b expression and concomitant p53 mutationAchim Temme, Kathrin D Geiger, Ralf Wiedemuth, et al.
Journal of Neuro-Oncology|February 13, 2015
Disseminated oligodendroglial-like leptomeningeal tumors: preliminary diagnostic and therapeutic results for a novel tumor entity [corrected]Matthias Preuss, Holger Christiansen, Andreas Merkenschlager, et al.
Hormone Research in Paediatrics|March 4, 2010
Analyses of treatment variables for patients with childhood craniopharyngioma--results of the multicenter prospective trial KRANIOPHARYNGEOM 2000 after three years of follow-upHermann L Müller, Ursel Gebhardt, Sabine Schröder, et al.
Pageof 39